Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8247730 | 0.81 | MEN1 (0.35) | MEN1MAPK1KMT2ACTSKHDAC4 | |
| SCHEMBL4615191 | 0.79 | MEN1 (0.34) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL13330959 | 0.79 | MEN1 (0.34) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL16062006 | 0.73 | MEN1 (0.38) | MEN1MAPK1KMT2ACTSK | |
| SCHEMBL15218631 | 0.73 | KMT2A (0.38) | SMN1; SMN2MEN1MAPK1KMT2AAPLNR | |
| SCHEMBL13817962 | 0.72 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1MAPK1KMT2AALDH1A1 | |
| SCHEMBL1537604 | 0.72 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1MAPK1KMT2AALDH1A1 | |
| SCHEMBL329899 | 0.72 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1MAPK1KMT2AALDH1A1 | |
| SCHEMBL5036319 | 0.72 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1MAPK1KMT2AALDH1A1 | |
| SCHEMBL3725588 | 0.72 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1MAPK1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300490-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, CTRB1 | SMN1; SMN2 4765/4885MEN1 4820/4885MAPK1 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.